ABSCF Stock: AB Science S.A. Stock Price, Analysis & Insights
Get live abscf stock price $1.27, comprehensive AB Science S.A. stock analysis, charts, news, and expert forecast. Real-time abscf stock data and investment insights.
Loading chart...
Company Overview
AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. It markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
Company Information
- CEO
- Alain Moussy
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 40
Contact Information
- Website
- https://www.ab-science.com
- Address
- 3, Avenue George V
- Country
- FR
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Higher growth potential with elevated volatility (Beta: 1.75)
Business Model & Strategy
AB Science S.A. operates in the Drug Manufacturers - Specialty & Generic industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Alain Moussy, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Drug Manufacturers - Specialty & Generic model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
AB Science S.A. competes in the Drug Manufacturers - Specialty & Generic within the broader Healthcare. With 84.1 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the Other OTC, AB Science S.A. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating AB Science S.A. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for AB Science S.A. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for AB Science S.A.
- ⚠Investors should consider how AB Science S.A. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
84.05M
P/E Ratio
-7.47
Beta
1.75
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 84.05M market capitalization
- Trading Volume: 1.45K shares traded today
- Price Range: 52-week range of $0.80 - $2.70
- Exchange: Listed on Other OTC
Financial Metrics
Market Analysis for AB Science S.A.
AB Science S.A. (ABSCF) operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. With a current market capitalization of 84.05M, the company represents a significant player in its market. The stock is currently trading at $1.27 with a positivedaily change of 0.00%.
The company's 40 employee base and presence on the Other OTCexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -7.47, beta of 1.75, and 52-week price range from $0.80 to $2.70when evaluating investment opportunities.
Why Invest in AB Science S.A.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (Other OTC)
- • Experienced leadership under Alain Moussy
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.